北京若生智能科技有限公司
Drug Database
AD

adenovirus vaccines

✓ Approved

Teva Pharmaceutical Industries Ltd. · 疫苗 · 疫苗

什么是 adenovirus vaccines？

adenovirus vaccines 是一种疫苗，由Teva Pharmaceutical Industries Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

公司Teva Pharmaceutical Industries Ltd.
药物类别疫苗, 大分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

治疗适应症

adenovirus vaccines 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAdenovirus infection✓ Approved

相关研究文献

PubMedInnovation (Cambridge (Mass.))2026-09-10

Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.

Wang Xinyue X, Su Shu S, Tan Siyi S, Chen Xiaosu X et al.

At the forefront of cancer immunotherapy, neoantigens are tumor specific and highly immunogenic, and they have emerged as the key target for personalized oncology. Neoantigen vaccines have demonstrated promising immunologic responses and survival benefit in clinical trials with the combination of chemoradiotherapy and immune checkpoint therapy. This review provides a comprehensive synthesis of biological mechanisms and the next-generation screening approach of cancer neoantigens. We evaluate the current vaccine platforms and the design and vector of cancer neoantigen vaccines, and we additionally analyze strategies to overcome immunosuppressive tumor microenvironment challenges. We conducted a detailed analysis of ongoing and preliminary neoantigen vaccine clinical trials, summarizing existing challenges and areas requiring further improvement. Through an in-depth analysis of the latest research advances, we propose current optimization strategies for neoantigen vaccines, including novel screening models and innovative delivery approaches. Future directions for personalized cancer immunotherapy are outlined, with neoantigen vaccines positioned as pivotal enabling platforms.

PMID 42719780
阅读全文 →
PubMedNature2026-09-10

Nasal vaccines could stop pandemics before they begin.

King Anthony A

PMID 42717071
阅读全文 →
PubMedJournal of the Pediatric Infectious Diseases Society2026-09-10

When Vaccination Meets Infection Prevention: National Practices for Inpatient Administration of Measles-Mumps-Rubella, Varicella, and Rotavirus Vaccines.

Altez Maria Susana Rueda MSR, Hutto Celia C, Hobby-Noland Delphene D, Song Xiaoyan X

PMID 42720270
阅读全文 →
PubMedJournal of medical virology2026-09-10

Emerging Trend of Notably High Prevalence of Human Enteric Adenovirus F41 Among Pediatric Patients With Acute Gastroenteritis in Thailand, 2022-2024.

Kumthip Kattareeya K, Yodmeeklin Arpaporn A, Khamrin Pattara P, Ushijima Hiroshi H et al.

Human adenovirus (HAdV) is one of the causative viral pathogens of acute gastroenteritis (AGE) in children worldwide, accounting for approximately 10% of diarrheal cases. To enhance understanding of the prevalence and epidemiology of HAdV infection, we conducted a 3-year molecular detection and characterization study of HAdV associated with AGE in Chiang Mai, Thailand, from 2022 to 2024. Among 1356 pediatric patients, HAdV was detected in 85 cases (6.3%). The highest HAdV infection rate was observed in 2023 (10.4%). HAdV infections were most frequently detected in children aged 3-4 years. Co-circulation of three HAdV species, including enteric HAdV-F and non-enteric HAdV-B and HAdV-C, was detected. Among these, six genotypes were identified, including HAdV-F41 (44.7%), HAdV-B3 (18.8%), HAdV-C1 (17.6%), HAdV-C5 (11.8%), HAdV-C2 (5.9%), and HAdV-B7 (1.2%). Notably, the emergence of HAdV-F41 was observed in 2023, accounting for 65.2% of HAdV-positive cases in that year. HAdV infections occurred year-round, with higher detection rates observed in June and August of 2023. In conclusion, this study demonstrates the prevalence, seasonality, and genotype diversity of HAdV infections among children with AGE in Thailand during 2022-2024. These findings indicate the co-circulation of enteric and non-enteric HAdVs in pediatric patients with AGE and provide valuable epidemiological insights for future surveillance and prevention strategies.

PMID 42720153
阅读全文 →
PubMedTransboundary and emerging diseases2026-09-10

Nanoparticle-Based Vaccines Against Toxoplasma gondii: Immunological Rationale, Platform Strategies, and Translational Challenges.

Sang Xiaoyu X, Zhang Yutong Y, Sun Fangqi F, Jin Yanting Y et al.

Toxoplasma gondii is a widely distributed zoonotic pathogen with detrimental impacts on both human health and livestock production. No vaccine is available for humans, and the only licensed veterinary vaccine, Toxovax, has limitations related to safety, stability, and large-scale production. In this review, we analyze nanoparticle platforms, including PLGA, chitosan, lipid nanoparticles, calcium phosphate nanoparticles, virus-like particles, and porous delivery systems, in relation to antigen uptake and MHC-I/MHC-II presentation, Th1-polarized cellular immunity, and mucosal vaccination. We also consider how antigen selection, carrier properties, route of administration, and host species influence immune responses and protection. Available studies show that different antigens may perform differently within the same platform and that the same antigen may induce different outcomes when delivered by different carriers. From a One Health perspective, feline vaccination may reduce environmental oocyst contamination, whereas livestock vaccination may reduce tissue cysts and food-borne transmission. Although parenteral mRNA-LNP vaccines have reduced chronic-stage parasite burdens in mice, direct evidence that they induce intestinal mucosal immunity remains limited. Key translational issues include validation in nonrodent hosts, chronic-stage and mucosal endpoints, manufacturing scalability, and regulatory approval. Nanoparticle vaccines remain promising, but their successful development will require closer matching of antigen, platform, administration route, and target host.

PMID 42717629
阅读全文 →
PubMedJournal of virology2026-09-10

Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.

Kirk James J, Sives Samantha S, Rayment Adam A, Tappin Amber A et al.

Infectious bronchitis virus (IBV), a Gammacoronavirus, causes the economically damaging disease of poultry, infectious bronchitis. Development of IBV live attenuated vaccines (LAVs) is dependent on the supply of embryonated hens' eggs and attenuation through serial passaging, upwards of 80 times. Vaccine development needs to keep pace with IBV evolution; an issue compounded as cross protection between individual IBV serotypes is unpredictable and often limited. Rational attenuation alongside the ability to propagate LAVs in cell culture offers significant advantages in terms of adaptability, cost, and speed. Most field IBV strains exhibit restricted in vitro tropism, being unable to replicate in primary or continuous cells without serial passage and adaptation. Beaudette, an attenuated IBV strain, is capable of replication in Vero cells, an ability conferred by the spike (S) glycoprotein. In this study, utilizing a recombinant IBV based on the nephropathogenic IBV strain D388, in which the S sequence is replaced with the equivalent sequence derived from Beaudette, we determine that the Beaudette spike can confer the ability to replicate in Vero cells and Beaudette's associated attenuated in vivo phenotype to a distantly related IBV strain. Assessment of infectious progeny and viral RNA in vivo suggests that attenuation was conferred by a tissue tropism-independent molecular mechanism. Analysis of innate immune responses revealed a lower intensity and less inflammatory profile. Our findings support the use of the Beaudette S protein as an avenue for the development of rationally attenuated, cell culture-propagated rIBV vaccines and identify the S protein as a contributor to nephropathogenicity.IMPORTANCEInfectious bronchitis virus (IBV), a Gammacoronavirus of chickens, causes significant economic losses worldwide. Current live attenuated vaccines (LAVs) are generated through extensive serial passage of virulent IBV strains in specific-pathogen-free (SPF) embryonated hen's eggs, upwards of 80 passages. This process is slow, dependent on the availability of SPF embryonated eggs, and the molecular basis of attenuation remains poorly understood. Development of rationally attenuated, cell-culture-based IBV vaccines would enable more rapid responses to emerging viral variants/strains. Using a recombinant IBV, we demonstrated the spike glycoprotein from the attenuated IBV strain Beaudette can confer attenuation and the ability to replicate in Vero cells to a distantly related virulent IBV strain. Attenuation was not linked to changes in tissue tropism but was associated with altered host responses. Our research provides new insights into IBV pathogenesis and presents an avenue for rational attenuation that can be exploited for future development of cell-based IBV vaccines.

PMID 42720295
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多adenovirus vaccines